Last reviewed · How we verify
Active comparator: DRV/cb
DRV/c (darunavir boosted with cobicistat) is a protease inhibitor combined with a pharmacokinetic booster that blocks HIV protease to prevent viral replication.
DRV/c (darunavir boosted with cobicistat) is a protease inhibitor combined with a pharmacokinetic booster that blocks HIV protease to prevent viral replication. Used for HIV-1 infection in treatment-experienced and treatment-naïve adults, HIV-1 infection in combination antiretroviral therapy.
At a glance
| Generic name | Active comparator: DRV/cb |
|---|---|
| Also known as | DARUNAVIR/COBICISTAT 800 Mg-150 Mg Oral Tablet |
| Sponsor | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud |
| Drug class | HIV protease inhibitor with pharmacokinetic booster |
| Target | HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Darunavir inhibits HIV protease, an enzyme essential for processing viral polyproteins and producing mature, infectious viral particles. Cobicistat is a cytochrome P450 inhibitor that boosts darunavir plasma concentrations, allowing for lower doses and improved tolerability. Together, they reduce viral load and slow disease progression in HIV-infected patients.
Approved indications
- HIV-1 infection in treatment-experienced and treatment-naïve adults
- HIV-1 infection in combination antiretroviral therapy
Common side effects
- Diarrhea
- Nausea
- Headache
- Rash
- Elevated liver enzymes
Key clinical trials
- Raltegravir One Thousand Two Hundred vs Darunavir-cb in Immnunosupressed Patients: ROTDIP Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: